Bristol’s Virology Focus Turning To Hepatitis B? An Interview With Doug Manion
At the AASLD conference, Bristol talked up its filing of a two-drug oral combination to treat hepatitis C in Japan, which would be the first oral combo regimen to reach market for the virus. But with plans to end discovery research in HCV, will the pharma focus its virology efforts more on hepatitis B and HIV?
You may also be interested in...
Two deals have resulted in the formerly shingles-focused biotech beginning to build an HBV pipeline and look ahead to therapeutic advances similar to those seen in HIV and hepatitis C. But the New Jersey biotech will be competing with some deep-pocketed competitors in the space.
With a focus on specialty drugs, Bristol wants to be known for more than immuno-oncology. To that end, specialty development head Douglas Manion is charged with leading innovation in immunology, virology and cardiovascular, genetically defined and fibrotic disease.
Long-time senior VP of R&D Francis Cuss will succeed Elliott Sigal as Bristol’s head of R&D on July 1, following a transition period. In an investor call, Cuss indicated no great change in strategy but acknowledged an ongoing need to evolve corporate thinking and capability.